NIGERIA NEUROPATHIC PAIN MANAGEMENT DRUGS MARKET ANALYSIS

Nigeria Neuropathic Pain Management Drugs Market, by Drug Class (Anticonvulsants, Serotonin–norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), and Others), by Disease Condition (Diabetic Neuropathy, Chemotherapy-induced Peripheral Neuropathy, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Feb 2022
Code : CMI4918
Pages :154
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Nigeria Neuropathic Pain Management Drugs Market: Restraint

The Nigeria pharmaceutical market suffers from several challenges such as scarce local production of pain management drugs, problem of counterfeit drugs, opioid drugs abuse (tramadol), heavy reliance on import of drugs from international manufacturers, and others. These factors are inadvertently affecting all the sectors of the pharmaceutical industry in Nigeria including the neuropathic pain management drugs market.

For instance, in November 2018, National Drug Law Enforcement Agency (NDLEA), Nigeria, seized 581 million Tramadol tablets which were illicitly brought into the country.

Moreover, other issues such as low awareness about neuropathic conditions and the management of these conditions, as well as lack of proper diagnostic techniques is expected to restrain growth of the neuropathic pain management drugs market in Nigeria over the forecast period.

The emerging opportunity for local production of neuropathic pain management drugs in the market is expected to drive growth of the Nigeria neuropathic pain management drugs market over the forecast period.

Presence of branded as well as generic versions of drugs for the treatment of neuropathic pain is expected to drive the market growth over the forecast period.